SI2363414T1 - Usmerjena modifikacija FVIII - Google Patents
Usmerjena modifikacija FVIIIInfo
- Publication number
- SI2363414T1 SI2363414T1 SI200532308T SI200532308T SI2363414T1 SI 2363414 T1 SI2363414 T1 SI 2363414T1 SI 200532308 T SI200532308 T SI 200532308T SI 200532308 T SI200532308 T SI 200532308T SI 2363414 T1 SI2363414 T1 SI 2363414T1
- Authority
- SI
- Slovenia
- Prior art keywords
- fviii
- site
- directed modification
- modification
- directed
- Prior art date
Links
- 102100026735 Coagulation factor VIII Human genes 0.000 title 1
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
- C07K17/08—Peptides being immobilised on, or in, an organic carrier the carrier being a synthetic polymer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62727704P | 2004-11-12 | 2004-11-12 | |
| EP11153300.6A EP2363414B1 (en) | 2004-11-12 | 2005-11-14 | Site-directed modification of FVIII |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2363414T1 true SI2363414T1 (sl) | 2022-09-30 |
Family
ID=36337298
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200532158T SI1824988T1 (sl) | 2004-11-12 | 2005-11-14 | Usmerjena modifikacija FVIII |
| SI200532283T SI3130601T1 (sl) | 2004-11-12 | 2005-11-14 | Usmerjena modifikacija FVIII |
| SI200532309T SI2371856T1 (sl) | 2004-11-12 | 2005-11-14 | Usmerjena modifikacija FVIII |
| SI200532308T SI2363414T1 (sl) | 2004-11-12 | 2005-11-14 | Usmerjena modifikacija FVIII |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200532158T SI1824988T1 (sl) | 2004-11-12 | 2005-11-14 | Usmerjena modifikacija FVIII |
| SI200532283T SI3130601T1 (sl) | 2004-11-12 | 2005-11-14 | Usmerjena modifikacija FVIII |
| SI200532309T SI2371856T1 (sl) | 2004-11-12 | 2005-11-14 | Usmerjena modifikacija FVIII |
Country Status (32)
Families Citing this family (107)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG155777A1 (en) | 2003-04-09 | 2009-10-29 | Neose Technologies Inc | Glycopegylation methods and proteins/peptides produced by the methods |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| US7579444B2 (en) * | 2004-06-30 | 2009-08-25 | Nektar Therapeutics Al, Corporation | Polymer-factor IX moiety conjugates |
| US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
| HUE026826T2 (en) | 2004-10-29 | 2016-07-28 | Ratiopharm Gmbh | Modeling and glycopegylation of fibroblast growth factor (FGF) |
| SI1824988T1 (sl) | 2004-11-12 | 2017-11-30 | Bayer Healthcare Llc | Usmerjena modifikacija FVIII |
| US9029331B2 (en) | 2005-01-10 | 2015-05-12 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
| EP1871795A4 (en) | 2005-04-08 | 2010-03-31 | Biogenerix Ag | COMPOSITIONS AND METHOD FOR PRODUCING GLYCOSYLATION MUTANTS OF A PROTEASE-RESISTANT HUMAN GROWTH HORMONE |
| WO2006134173A2 (en) | 2005-06-17 | 2006-12-21 | Novo Nordisk Health Care Ag | Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine |
| US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
| BRPI0712008A2 (pt) * | 2006-05-24 | 2012-01-10 | Novo Nordisk Healthcare Ag | derivados e análogos de fix prolongados |
| US20080248959A1 (en) | 2006-07-21 | 2008-10-09 | Neose Technologies, Inc. | Glycosylation of peptides via o-linked glycosylation sequences |
| JP2010505874A (ja) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー／エス | ポリペプチドコンジュゲートの精製方法 |
| CN105838699A (zh) | 2006-12-15 | 2016-08-10 | 巴克斯艾尔塔公司 | 具有延长的体内半衰期的因子VIIa-聚唾液酸结合物 |
| RS52845B (sr) | 2007-04-03 | 2013-12-31 | Biogenerix Ag | Postupci tretmana korišćenjem glikopegiliranog g-csf |
| JP5876649B2 (ja) | 2007-06-12 | 2016-03-02 | ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ | ヌクレオチド糖の改良製造法 |
| BRPI0820271A2 (pt) * | 2007-11-09 | 2015-05-26 | Baxter Int | Métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii que inibe receptores de depruração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de ...métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii pela inibição da interação com um receptor de depuração, de preparar uma composição que inibe receptores de depuração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de coagulação modificada. |
| ES2476690T3 (es) | 2008-02-27 | 2014-07-15 | Novo Nordisk A/S | Moléculas conjugadas del Factor VIII |
| CN104059155A (zh) | 2008-05-16 | 2014-09-24 | 拜耳医药保健有限公司 | 靶向性凝固因子及其使用方法 |
| CN102112623A (zh) * | 2008-06-04 | 2011-06-29 | 拜耳医药保健有限公司 | 用于治疗血管性血友病的fviii突变蛋白 |
| CN103739712B (zh) | 2008-06-24 | 2016-10-05 | 德国杰特贝林生物制品有限公司 | 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物 |
| WO2010019263A2 (en) * | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
| HUE039906T2 (hu) * | 2008-10-17 | 2019-02-28 | Baxalta GmbH | Alacsony fokú vízben oldható polimer tartalmú módosított vérfaktorok |
| KR20110093775A (ko) * | 2008-11-03 | 2011-08-18 | 바이엘 헬스케어 엘엘씨 | 혈우병 치료 방법 |
| WO2010060081A1 (en) * | 2008-11-24 | 2010-05-27 | Bayer Healthcare Llc | Method of determining pegylated blood coagulation factor activity in a silica-based activated partial thromboplastin time assay |
| US20120121613A1 (en) * | 2009-01-19 | 2012-05-17 | Bayer Healthcare Llc | Protein conjugate having an endopeptidase- cleavable bioprotective moiety |
| WO2010091122A1 (en) | 2009-02-03 | 2010-08-12 | Amunix, Inc. | Extended recombinant polypeptides and compositions comprising same |
| CN102333788A (zh) * | 2009-02-19 | 2012-01-25 | 诺沃—诺迪斯克有限公司 | 因子viii的修饰 |
| AU2010225523B2 (en) * | 2009-03-20 | 2012-05-24 | Hanmi Science Co., Ltd. | Method for preparing a site-specific physiologically active polypeptide conjugate |
| CN102427823A (zh) * | 2009-03-24 | 2012-04-25 | 拜耳医药保健有限公司 | 因子viii变体及使用方法 |
| EP2459224B1 (en) | 2009-07-27 | 2016-06-01 | Baxalta GmbH | Blood coagulation protein conjugates |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| PL2459224T3 (pl) | 2009-07-27 | 2017-08-31 | Baxalta GmbH | Koniugaty białka związanego z krzepnięciem krwi |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| EP2459226B1 (en) | 2009-07-27 | 2016-06-29 | Lipoxen Technologies Limited | Glycopolysialylation of proteins other than blood coagulation proteins |
| BR112012004094A2 (pt) | 2009-08-24 | 2016-03-08 | Amunix Operating Inc | composições de fator vii de coagulação e métodos para fazer e usar as mesmas |
| MX353233B (es) | 2009-12-06 | 2018-01-08 | Bioverativ Therapeutics Inc | Polipéptidos híbridos y quiméricos del factor viii-fc, y métodos de uso de los mismos. |
| US8765432B2 (en) | 2009-12-18 | 2014-07-01 | Oligasis, Llc | Targeted drug phosphorylcholine polymer conjugates |
| EP2536753B1 (en) | 2010-02-16 | 2017-12-20 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
| BR112012020855B8 (pt) * | 2010-02-21 | 2021-05-25 | Bayer Healthcare Llc | método para produzir um conjugado de biomolécula |
| KR20200067958A (ko) | 2010-04-15 | 2020-06-12 | 코디악 사이언시스 인코포레이티드 | 고분자량 쌍성이온-함유 중합체 |
| GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| US9611310B2 (en) | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
| US9150637B2 (en) * | 2010-11-05 | 2015-10-06 | Baxalta Inc. | Variant of antihemophilic factor VIII having increased specific activity |
| WO2012079979A1 (en) * | 2010-12-16 | 2012-06-21 | Novo Nordisk A/S | Aqueous factor viii solution |
| ES2800983T3 (es) | 2010-12-22 | 2021-01-07 | Baxalta GmbH | Materiales y métodos para conjugar un derivado de ácido graso soluble en agua con una proteína |
| CA2836478A1 (en) | 2011-05-27 | 2012-12-06 | Baxter International Inc. | Therapeutic protein conjugated to water-soluble polymers via reduced cysteine sulfhydryl group |
| DK2717898T3 (en) | 2011-06-10 | 2019-03-25 | Bioverativ Therapeutics Inc | COAGULATING COMPOUNDS AND PROCEDURES FOR USE THEREOF |
| MX2014000031A (es) | 2011-07-01 | 2014-07-09 | Bayer Ip Gmbh | Polipeptidos de fusion de relaxina y usos de los mismos. |
| DK3513804T3 (da) | 2011-07-08 | 2022-06-20 | Bioverativ Therapeutics Inc | Kimære og hybride faktor viii-polypeptider og fremgangsmåder til anvendelse deraf |
| WO2013041678A1 (en) | 2011-09-23 | 2013-03-28 | Novo Nordisk A/S | Novel glucagon analogues |
| KR20130049671A (ko) * | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
| ES2651523T3 (es) | 2012-02-15 | 2018-01-26 | Csl Behring Gmbh | Variantes del Factor de von Willebrand que tienen afinidad de unión al Factor VIII mejorada |
| LT2822577T (lt) | 2012-02-15 | 2019-03-25 | Bioverativ Therapeutics Inc. | Rekombinantiniai faktoriaus viii baltymai |
| HRP20221531T1 (hr) | 2012-02-15 | 2023-02-17 | Bioverativ Therapeutics Inc. | Pripravci faktora viii i postupci dobivanja i korištenja istih |
| EP2666782A1 (en) | 2012-05-22 | 2013-11-27 | Imnate Sarl | Coagulation factor VIII with reduced immunogenicity. |
| CA2875246A1 (en) | 2012-06-08 | 2013-12-12 | Biogen Idec Ma Inc. | Procoagulant compounds |
| WO2014008480A2 (en) | 2012-07-06 | 2014-01-09 | Biogen Idec Ma Inc. | Cell line expressing single chain factor viii polypeptides and uses thereof |
| CA2888806A1 (en) | 2012-10-18 | 2014-04-24 | Biogen Idec Ma Inc. | Methods of using a fixed dose of a clotting factor |
| HK1214539A1 (zh) | 2012-10-30 | 2016-07-29 | Bioverativ Therapeutics Inc. | 應用viii因子多肽的方法 |
| EA037906B1 (ru) | 2013-03-15 | 2021-06-04 | Биовератив Терапьютикс Инк. | Препараты полипептида фактора ix |
| PE20160121A1 (es) * | 2013-03-15 | 2016-03-03 | Bayer Healthcare Llc | Formulaciones de factor viii recombinantes |
| PL3666283T3 (pl) | 2013-03-15 | 2022-10-03 | Bioverativ Therapeutics Inc. | Formulacje polipeptydu czynnika viii |
| RU2683039C2 (ru) | 2013-04-18 | 2019-03-26 | Ново Нордиск А/С | Стабильные совместные агонисты рецептора глюкагоноподобного пептида-1/глюкагона пролонгированного действия для медицинского применения |
| DK2796145T3 (da) | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
| TW201519900A (zh) * | 2013-04-28 | 2015-06-01 | Bayer Healthcare Llc | 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法 |
| US20160311885A1 (en) | 2013-08-14 | 2016-10-27 | Biogen Ma Inc. | Recombinant factor viii proteins |
| EP3033097B1 (en) | 2013-08-14 | 2021-03-10 | Bioverativ Therapeutics Inc. | Factor viii-xten fusions and uses thereof |
| JP6463361B2 (ja) | 2013-09-08 | 2019-01-30 | コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． | 第ｖｉｉｉ因子両性イオンポリマーコンジュゲート |
| KR20160090810A (ko) * | 2013-10-22 | 2016-08-01 | 디비브이 테크놀로지스 (소시에떼 아노님) | 혈액 인자에 대한 관용 유도에 의한 혈우병의 치료 방법 |
| WO2015070014A1 (en) | 2013-11-08 | 2015-05-14 | Biogen Idec Ma Inc. | Procoagulant fusion compound |
| RU2546297C1 (ru) * | 2013-11-19 | 2015-04-10 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук | Средство, улучшающее реологические свойства крови |
| EP3082848B1 (en) | 2013-12-06 | 2023-10-18 | Bioverativ Therapeutics Inc. | Population pharmacokinetics tools and uses thereof |
| EP3097118B1 (en) | 2014-01-20 | 2018-07-18 | Octapharma AG | A process for manufacturing factor viii having an improved ratio of fviii:c/fviii:ag |
| KR102382402B1 (ko) | 2014-02-04 | 2022-04-01 | 바이오젠 엠에이 인코포레이티드 | 번역 후 변형을 강화시키기 위한 통류 방식 양이온 교환 크로마토그래피의 용도 |
| EP3114138B1 (en) | 2014-03-05 | 2021-11-17 | Pfizer Inc. | Improved muteins of clotting factor viii |
| SG10201913735SA (en) | 2014-03-24 | 2020-03-30 | Bioverativ Therapeutics Inc | Lyophilized factor ix formulations |
| US11181534B2 (en) * | 2014-04-04 | 2021-11-23 | Bloodworks | Routine laboratory and point-of-care (POC) testing for hemostasis |
| CN106459907B (zh) | 2014-04-10 | 2020-11-06 | 拜尔健康护理有限责任公司 | 复合培养基粉末制剂和制备用于细胞培养的液体培养基的方法 |
| JP2017525656A (ja) | 2014-06-04 | 2017-09-07 | ノヴォ ノルディスク アー／エス | 医療用のｇｌｐ−１／グルカゴン受容体コアゴニスト |
| AU2015283822B2 (en) | 2014-07-02 | 2019-10-03 | CSL Behring Lengnau AG | Modified von willebrand factor |
| MA40864A (fr) | 2014-10-31 | 2017-09-05 | Biogen Ma Inc | Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères |
| DK3265483T3 (da) | 2015-03-06 | 2020-03-02 | CSL Behring Lengnau AG | Modificeret von Willebrand-faktor med forbedret halveringstid |
| SG11201708755WA (en) | 2015-05-22 | 2017-12-28 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for treating hemophilia |
| CN107810194B (zh) | 2015-05-22 | 2021-10-08 | 康诺贝林伦瑙有限公司 | 用于制备经修饰的血管性血友病因子的方法 |
| MX2018001497A (es) | 2015-08-03 | 2018-05-15 | Bioverativ Therapeutics Inc | Proteinas de fusion de factor ix y metodos para producirlas y usarlas. |
| US9849125B1 (en) | 2015-11-03 | 2017-12-26 | Banner Lifie Sciences LLC | Anti-overingestion dosage forms |
| SG10201912857XA (en) | 2016-01-07 | 2020-02-27 | CSL Behring Lengnau AG | Mutated von willebrand factor |
| SG11201805497QA (en) | 2016-01-07 | 2018-07-30 | Csl Behring Recombinant Facility Ag | Mutated truncated von willebrand factor |
| CN109689683A (zh) * | 2016-06-24 | 2019-04-26 | 财团法人牧岩生命科学研究所 | 重组单链fvⅲ及其化学缀合物 |
| AU2017358865A1 (en) | 2016-11-11 | 2019-05-09 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| TW201828975A (zh) | 2016-11-11 | 2018-08-16 | 瑞士商Ｃｓｌ貝林重組技能公司 | 用於治療血友病之截短型類血友病因子（ｖｏｎ Ｗｉｌｌｅｂｒａｎｄ ｆａｃｔｏｒ）多肽類 |
| BR112019010034A2 (pt) | 2016-11-16 | 2019-09-03 | Bayer Healthcare Llc | fator viii alvejado de hemácia e método de uso do mesmo |
| WO2018102743A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of treating hemophilic arthropathy using chimeric clotting factors |
| BR112019011198A2 (pt) | 2016-12-02 | 2019-12-17 | Bioverativ Therapeutics Inc | métodos de indução de tolerância imune a fatores de coagulação |
| EA201991768A1 (ru) | 2017-01-31 | 2020-01-22 | Байоверетив Терапьютикс Инк. | Слитые белки на основе фактора ix и способы их получения и пути применения |
| US10335375B2 (en) | 2017-05-30 | 2019-07-02 | Patheon Softgels, Inc. | Anti-overingestion abuse deterrent compositions |
| KR20190086269A (ko) * | 2018-01-12 | 2019-07-22 | 재단법인 목암생명과학연구소 | 체내 지속형 재조합 당단백질 및 이의 제조방법 |
| MA53020A (fr) | 2018-05-18 | 2021-05-05 | Zhengzhou Gensciences Inc | Protéine de fusion du fviii améliorée et utilisation associée |
| RS66972B1 (sr) | 2018-05-18 | 2025-07-31 | Bioverativ Therapeutics Inc | Metode lečenja hemofilije a |
| WO2021072265A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021091881A1 (en) * | 2019-11-04 | 2021-05-14 | The Trustees Of Columbia University In The City Of New York | High concentration cell penetrating caspase inhibitor conjugates compositions and methods thereof |
| WO2021113800A1 (en) * | 2019-12-06 | 2021-06-10 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor viii function |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59172425A (ja) * | 1983-03-18 | 1984-09-29 | Nippon Chemiphar Co Ltd | 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤 |
| US7138505B1 (en) | 1984-01-12 | 2006-11-21 | Novartis Vaccines And Diagnostics, Inc. | Factor VIII:C nucleic acid molecules |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| US5422260A (en) | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
| US5451521A (en) | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
| EP0690126B1 (en) | 1987-06-12 | 2001-11-28 | Baxter Aktiengesellschaft | Novel proteins with factor VIII activitiy: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| IL86693A (en) | 1987-06-12 | 1994-06-24 | Stichting Centraal Lab | Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them |
| AU2473388A (en) * | 1987-11-16 | 1989-06-22 | Scripps Clinic And Research Foundation | Treatment of factor viii inhibitors |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| US5766897A (en) | 1990-06-21 | 1998-06-16 | Incyte Pharmaceuticals, Inc. | Cysteine-pegylated proteins |
| US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
| US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
| ATE316981T1 (de) | 1992-10-02 | 2006-02-15 | Inst Genetics Llc | Zusammensetzung, welche den koagulationsfaktor viii beinhalted; verfahren zu deren herstellung und die benutzung eines oberflächenaktiven stoffes als stabilisator |
| WO1994015625A1 (en) | 1993-01-15 | 1994-07-21 | Enzon, Inc. | Factor viii - polymeric conjugates |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| EP0730660A4 (en) | 1993-10-29 | 1998-02-25 | Incyte Pharma Inc | CHIMEAN PROTEINE PROTEASE NEXIN-1 CONTAINING VARIANTS |
| IL113010A (en) | 1994-03-31 | 1999-10-28 | Pharmacia & Upjohn Ab | Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration |
| BE1008491A3 (fr) * | 1994-07-14 | 1996-05-07 | Croix Rouge De Belgique Depart | Sequence polypeptidique antigenique du facteur viii, fragments et/ou epitopes de celle-ci. |
| WO1996041813A2 (en) | 1994-11-09 | 1996-12-27 | Offord Robin E | Functionalized polymers for site-specific attachment |
| CA2198111C (en) * | 1995-06-21 | 2000-01-11 | James Patrick Phillips | Method and antenna for providing an omnidirectional pattern |
| WO1997003195A1 (en) | 1995-07-11 | 1997-01-30 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered protease sites |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| AT403438B (de) | 1996-05-24 | 1998-02-25 | Immuno Ag | Pharmazeutische präparation mit faktor viii prokoagulationsaktivität und vwf-bindungsaktivität |
| US6458563B1 (en) * | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| DE69736780T2 (de) * | 1996-08-02 | 2007-09-06 | Ortho-Mcneil Pharmaceutical, Inc. | Polypeptide mit einzelnem kovalent gebundenen n-terminalen wasserlöslichen polymer |
| CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
| WO2000042175A1 (en) | 1999-01-14 | 2000-07-20 | Bolder Biotechnology Inc. | Methods for making proteins containing free cysteine residues |
| EP1012184B1 (en) | 1997-07-14 | 2007-10-10 | Bolder Biotechnology, Inc. | Derivatives of growth hormone and related proteins |
| US6753165B1 (en) * | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
| CN1113656C (zh) * | 1997-10-17 | 2003-07-09 | 丰收技术股份有限公司 | 从富含血小板的血浆中沉淀富集生长因子的纤维蛋白原浓缩物 |
| EP0922446A1 (en) | 1997-12-03 | 1999-06-16 | Applied Research Systems Ars Holding N.V. | Solution-phase site-specific preparation of GRF-PEG conjugates |
| MXPA00010241A (es) | 1998-04-27 | 2004-09-06 | Opperbas Holding Bv | Composicion farmaceutica que comprende el factor viii y liposomas neutrales.. |
| US6759216B1 (en) | 1998-11-06 | 2004-07-06 | Emory University | Glycosylated, low antigenicity low immunogenicity factor VIII |
| CA2349468C (en) | 1998-11-10 | 2013-07-09 | Baxter Aktiengesellschaft | Factor viii polypeptide having factor viii:c activity |
| US6136599A (en) | 1998-12-10 | 2000-10-24 | Bayer Corporation | Human hybrid host cell for mammalian gene expression |
| US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
| EP1183354A2 (en) | 1999-05-24 | 2002-03-06 | The American National Red Cross | Methods of reducing factor viii clearance and compositions therefor |
| WO2001058935A2 (en) * | 2000-02-11 | 2001-08-16 | Maxygen Aps | FACTOR VII OR VIIa-LIKE MOLECULES |
| WO2002024723A1 (en) | 2000-09-19 | 2002-03-28 | Emory University | Modified factor viii |
| JP2005518181A (ja) | 2001-01-12 | 2005-06-23 | ジ・アメリカン・ナショナル・レッド・クロス | 第ｖｉｉｉ因子のヘパラン硫酸プロテオグリカン仲介性クリアランスを低下させるための方法および組成物 |
| WO2002077218A1 (en) * | 2001-03-22 | 2002-10-03 | Novo Nordisk Health Care Ag | Coagulation factor vii derivatives |
| WO2002096454A1 (en) | 2001-05-31 | 2002-12-05 | D. Collen Research Foundation Vzw | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
| AU2002312660A1 (en) | 2001-05-31 | 2002-12-16 | D. Collen Research Foundation Vzw Onderwijsen Navorsing Campus Gasthuisberg K.U. Leuven | Recombinant molecules with reduced immunogenicity, methods and intermediates for obtaining them and their use in pharmaceutical compositions and diagnostic tools |
| EP2110385A1 (en) | 2001-06-14 | 2009-10-21 | The Scripps Research Institute | Stabilized factor VIII with engineered disulfide bonds |
| CA2461443C (en) | 2001-10-05 | 2011-07-12 | Emory University | Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use |
| JP2005538694A (ja) | 2002-04-18 | 2005-12-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 修飾されたｖｉｉｉ因子 |
| US8003117B2 (en) | 2002-11-20 | 2011-08-23 | Nof Corporation | Polyalkylene glycol derivative and modified bio-related substance |
| JP4412461B2 (ja) | 2002-11-20 | 2010-02-10 | 日油株式会社 | 修飾された生体関連物質、その製造方法および中間体 |
| MXPA05007163A (es) | 2002-12-31 | 2005-09-21 | Nektar Therapeutics Al Corp | Derivados polimericos de acido maleamico y sus bioconjugados. |
| KR101025143B1 (ko) | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | 가수분해상으로 안정한 말레이미드－종결 중합체 |
| ATE485331T1 (de) | 2003-01-06 | 2010-11-15 | Nektar Therapeutics | Thiolselektive wasserlösliche polymerderivate |
| AU2004215912B2 (en) | 2003-02-26 | 2009-03-26 | Nektar Therapeutics | Polymer-factor VIII moiety conjugates |
| US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| US20040180054A1 (en) | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| EP1626983B8 (en) | 2003-05-12 | 2010-12-22 | Affymax, Inc. | Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof |
| KR101128320B1 (ko) | 2003-05-23 | 2012-04-12 | 넥타르 테라퓨틱스 | 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체 |
| EP1502921A1 (en) | 2003-07-29 | 2005-02-02 | ZLB Behring GmbH | Recombinant mutated human factor VIII (FVIII) with improved stability |
| US20050123997A1 (en) | 2003-10-30 | 2005-06-09 | Lollar John S. | Modified fVIII having reduced immunogenicity through mutagenesis of A2 and C2 epitopes |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| US7855274B2 (en) | 2003-12-03 | 2010-12-21 | University Of Rochester | Recombinant factor VIII having increased specific activity |
| WO2006027111A1 (en) | 2004-09-06 | 2006-03-16 | Zlb Behring Gmbh | Modified coagulation factor viii with enhanced stability |
| SI1824988T1 (sl) | 2004-11-12 | 2017-11-30 | Bayer Healthcare Llc | Usmerjena modifikacija FVIII |
| JP2008534559A (ja) | 2005-04-01 | 2008-08-28 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 血液凝固ｆｖｉｉｉ類似体 |
| US7645860B2 (en) | 2006-03-31 | 2010-01-12 | Baxter Healthcare S.A. | Factor VIII polymer conjugates |
| NZ572050A (en) | 2006-03-31 | 2011-09-30 | Baxter Int | Factor VIII conjugated to polyethylene glycol |
-
2005
- 2005-11-14 SI SI200532158T patent/SI1824988T1/sl unknown
- 2005-11-14 EP EP11153297.4A patent/EP2371856B1/en not_active Expired - Lifetime
- 2005-11-14 PT PT111532974T patent/PT2371856T/pt unknown
- 2005-11-14 KR KR1020127028644A patent/KR20120136413A/ko not_active Ceased
- 2005-11-14 KR KR1020167023706A patent/KR101904630B1/ko not_active Expired - Fee Related
- 2005-11-14 LT LTEP11153300.6T patent/LT2363414T/lt unknown
- 2005-11-14 EP EP17166910.4A patent/EP3243833B1/en not_active Expired - Lifetime
- 2005-11-14 PT PT111533006T patent/PT2363414T/pt unknown
- 2005-11-14 KR KR1020147002721A patent/KR101483917B1/ko not_active Expired - Lifetime
- 2005-11-14 NZ NZ555032A patent/NZ555032A/en not_active IP Right Cessation
- 2005-11-14 HR HRP20180481AA patent/HRP20180481B1/hr not_active IP Right Cessation
- 2005-11-14 NO NO20200044A patent/NO345800B1/no unknown
- 2005-11-14 MX MX2007005466A patent/MX2007005466A/es active IP Right Grant
- 2005-11-14 ES ES11153300T patent/ES2930159T3/es not_active Expired - Lifetime
- 2005-11-14 DK DK11153300.6T patent/DK2363414T3/da active
- 2005-11-14 ES ES11153297T patent/ES2930143T3/es not_active Expired - Lifetime
- 2005-11-14 KR KR1020187027821A patent/KR20180110192A/ko not_active Ceased
- 2005-11-14 US US11/273,896 patent/US7632921B2/en active Active
- 2005-11-14 LT LTEP11153297.4T patent/LT2371856T/lt unknown
- 2005-11-14 RU RU2007121517/10A patent/RU2423380C2/ru active
- 2005-11-14 EP EP14165736.1A patent/EP2772500B1/en not_active Revoked
- 2005-11-14 DK DK05849392.5T patent/DK1824988T3/en active
- 2005-11-14 ES ES05849392.5T patent/ES2633916T3/es not_active Expired - Lifetime
- 2005-11-14 CN CN201210455152.1A patent/CN103102406B/zh not_active Expired - Lifetime
- 2005-11-14 SI SI200532283T patent/SI3130601T1/sl unknown
- 2005-11-14 KR KR1020147018134A patent/KR101654011B1/ko not_active Expired - Fee Related
- 2005-11-14 CN CN201610838893.6A patent/CN107082806A/zh active Pending
- 2005-11-14 UA UAA200706559A patent/UA95225C2/ru unknown
- 2005-11-14 CA CA2586379A patent/CA2586379C/en not_active Expired - Lifetime
- 2005-11-14 BR BR122016022033A patent/BR122016022033B8/pt active IP Right Grant
- 2005-11-14 MX MX2017007144A patent/MX392760B/es unknown
- 2005-11-14 BR BRPI0517795A patent/BRPI0517795B8/pt active IP Right Grant
- 2005-11-14 EP EP05849392.5A patent/EP1824988B1/en not_active Expired - Lifetime
- 2005-11-14 MX MX2014005051A patent/MX350293B/es unknown
- 2005-11-14 PT PT161869011T patent/PT3130601T/pt unknown
- 2005-11-14 HU HUE11153297A patent/HUE059193T2/hu unknown
- 2005-11-14 AU AU2005304622A patent/AU2005304622B2/en not_active Expired
- 2005-11-14 CN CN201310125428.4A patent/CN103214569B/zh not_active Expired - Lifetime
- 2005-11-14 CN CN201510612184.1A patent/CN105148287B/zh not_active Expired - Fee Related
- 2005-11-14 EP EP17170687.2A patent/EP3243834A1/en not_active Withdrawn
- 2005-11-14 NO NO20210454A patent/NO20210454A1/no unknown
- 2005-11-14 HU HUE11153300A patent/HUE060016T2/hu unknown
- 2005-11-14 HU HUE16186901A patent/HUE050542T2/hu unknown
- 2005-11-14 EP EP11153300.6A patent/EP2363414B1/en not_active Expired - Lifetime
- 2005-11-14 LT LTEP16186901.1T patent/LT3130601T/lt unknown
- 2005-11-14 ES ES16186901T patent/ES2821832T3/es not_active Expired - Lifetime
- 2005-11-14 CN CN201610201090.XA patent/CN105753968A/zh active Pending
- 2005-11-14 PL PL05849392T patent/PL1824988T3/pl unknown
- 2005-11-14 CN CN2005800464698A patent/CN101124331B/zh not_active Expired - Lifetime
- 2005-11-14 EP EP17201672.7A patent/EP3323829B1/en not_active Expired - Lifetime
- 2005-11-14 JP JP2007541405A patent/JP2008524117A/ja active Pending
- 2005-11-14 KR KR1020137007423A patent/KR101468345B1/ko not_active Expired - Fee Related
- 2005-11-14 SI SI200532309T patent/SI2371856T1/sl unknown
- 2005-11-14 PT PT58493925T patent/PT1824988T/pt unknown
- 2005-11-14 KR KR1020077013131A patent/KR101243564B1/ko not_active Expired - Lifetime
- 2005-11-14 PL PL11153300.6T patent/PL2363414T3/pl unknown
- 2005-11-14 EP EP16186901.1A patent/EP3130601B1/en not_active Expired - Lifetime
- 2005-11-14 LT LTEP05849392.5T patent/LT1824988T/lt unknown
- 2005-11-14 EP EP16186902.9A patent/EP3153181A1/en not_active Withdrawn
- 2005-11-14 HU HUE05849392A patent/HUE033776T2/en unknown
- 2005-11-14 SI SI200532308T patent/SI2363414T1/sl unknown
- 2005-11-14 WO PCT/US2005/041205 patent/WO2006053299A2/en not_active Ceased
- 2005-11-14 DK DK11153297.4T patent/DK2371856T3/da active
- 2005-11-14 PL PL11153297.4T patent/PL2371856T3/pl unknown
- 2005-11-14 HR HRP20070268AA patent/HRP20070268B1/hr not_active IP Right Cessation
-
2007
- 2007-05-01 IL IL182903A patent/IL182903A/en active IP Right Grant
- 2007-05-08 ZA ZA200703696A patent/ZA200703696B/xx unknown
- 2007-05-11 HN HN2007015683A patent/HN2007015683A/es unknown
- 2007-06-06 MA MA29972A patent/MA29663B1/fr unknown
- 2007-06-12 NO NO20072997A patent/NO344606B1/no unknown
-
2009
- 2009-08-13 US US12/540,703 patent/US9364520B2/en active Active
-
2012
- 2012-10-19 JP JP2012231926A patent/JP6109523B2/ja not_active Expired - Lifetime
-
2013
- 2013-01-24 US US13/748,983 patent/US9096656B2/en not_active Expired - Lifetime
-
2014
- 2014-02-12 PH PH12014500352A patent/PH12014500352B1/en unknown
- 2014-05-11 IL IL232540A patent/IL232540A/en active IP Right Grant
- 2014-09-02 IL IL23443314A patent/IL234433B/en active IP Right Grant
-
2015
- 2015-02-09 JP JP2015022993A patent/JP6018238B2/ja not_active Expired - Lifetime
- 2015-07-20 US US14/803,677 patent/US20160051633A1/en not_active Abandoned
-
2016
- 2016-12-02 JP JP2016234756A patent/JP6487895B2/ja not_active Expired - Fee Related
- 2016-12-02 JP JP2016234757A patent/JP6559642B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-14 CY CY20171100753T patent/CY1119292T1/el unknown
-
2019
- 2019-05-07 HU HUS1900026C patent/HUS1900026I1/hu unknown
- 2019-05-07 FR FR19C1031C patent/FR19C1031I2/fr active Active
- 2019-05-07 BE BE2019C523C patent/BE2019C523I2/nl unknown
- 2019-05-08 LU LU00118C patent/LUC00118I2/fr unknown
- 2019-05-09 LT LTPA2019509C patent/LTC1824988I2/lt unknown
- 2019-05-10 NL NL300989C patent/NL300989I2/nl unknown
- 2019-05-10 CY CY2019024C patent/CY2019024I1/el unknown
- 2019-07-09 PH PH12019501613A patent/PH12019501613A1/en unknown
-
2020
- 2020-10-05 CY CY20201100928T patent/CY1123384T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL234433B (en) | Site-directed modification of factor viii | |
| GB0524619D0 (en) | Improved osteotome | |
| IL183634A0 (en) | Polymer-von willebrand factor-conjugates | |
| EP1773871A4 (en) | COMPOUNDS ASSOCIATED WITH TISSUE DIFFERENTIATION FACTOR AND THEIR ANALOGUES | |
| EP1785131A4 (en) | EXTERNAL PREPARATION OF TYPE S / O | |
| ZA200606315B (en) | Novel amido-substituted hydroxy-6-phenylphenanthridines | |
| AU300055S (en) | Scrubber | |
| PL1720633T3 (pl) | Płuczka wieżowa gazu | |
| GB0428026D0 (en) | Infant aid | |
| GB0517332D0 (en) | Improved building components | |
| GB2416051B (en) | Selection of component | |
| ZA200508325B (en) | Manufacture of kerbstones | |
| GB0421155D0 (en) | Piece of mind plan | |
| GB0415217D0 (en) | Compounds and uses thereof | |
| GB0412872D0 (en) | Novel structures | |
| PL369353A1 (pl) | Zestaw elementów budowlanych | |
| AU157294S (en) | External cornice corner member | |
| TWM275831U (en) | Improved structure of cinerary urn | |
| SI1835938T1 (sl) | Konjugati polimera in von Willebrandovega faktorja | |
| GB0415721D0 (en) | Novel preparation | |
| GB0414968D0 (en) | Novel preparation | |
| GB0402464D0 (en) | Child walker |